The safety and clinical effectiveness of rapid infusion with CT‐P10 in patients with non‐Hodgkin's lymphoma or chronic lymphocytic leukemia: A retrospective non‐interventional post‐authorization safety study in Europe-Reference-Cited by-同舟云学术

The safety and clinical effectiveness of rapid infusion with CT‐P10 in patients with non‐Hodgkin's lymphoma or chronic lymphocytic leukemia: A retrospective non‐interventional post‐authorization safety study in Europe

Published:2022-03-17 Issue:3 Volume:40 Page:370-380
ISSN:0278-0232
Container-title:Hematological Oncology
language:en
Short-container-title:Hematological Oncology

Author:

Bishton Mark¹,Marshall Scott²,Harchowal Jatinder³,Salles Gilles⁴,Golfier Camille⁴,Tucci Alessandra⁵,Fernández Alicia Rodriguez⁶,Sanchez Blanco Jose Javier⁷,Bocchia Monica⁸,Kim SooKyoung⁹,Lee Young Nam⁹,Zinzani Pier Luigi¹⁰¹¹^ORCID

Affiliation:

1. Nottingham City Hospital Nottingham University Hospitals NHS Trust Nottingham UK

2. Sunderland Royal Hospital South Tyneside and Sunderland NHS Foundation Trust Sunderland UK

3. The Royal Marsden NHS Foundation Trust London UK

4. Centre Hospitalier Lyon Sud ‐ Service d’Hématologie Clinique Lyon France

5. Hematology Department ASST Spedali Civili di Brescia Brescia Italy

6. Hematology Department Hospital Universitario Virgen de la Macarena Seville Spain

7. Hematology Department Hospital Morales Meseguer de Murcia Murcia Spain

8. U.O.C Ematologia, Azienda Ospedaliero‐Universitaria Senese ‐ Policlinico Santa Maria alle Scotte Siena Italy

9. Celltrion Healthcare Co. Ltd. Incheon Republic of Korea

10. IRCCS Azienda Ospedaliero‐Universitaria di Bologna, Istituto di Ematologia “Seràgnoli” Bologna Italy

11. Dipartimento di Medicina Specialistica e Sperimentale Università di Bologna Bologna Italy

Funder

Celltrion Healthcare

Publisher

Wiley

Subject

Cancer Research,Oncology,Hematology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/hon.2978

Reference24 articles.

1. Celltrion Healthcare. Truxima 500 mg concentrate for solution for infusion: EU summary of product characteristics. 2017. Accessed January 22 2018.http://ec.europa.eu/health/documents/community‐register/html/h1167.htm

2. Comparison of biosimilar CT-P10 and innovator rituximab in patients with rheumatoid arthritis: a randomized controlled Phase 3 trial